Skip to search formSkip to main contentSkip to account menu

ibalizumab

Known as: Immunoglobulin G4, Anti-(Human CD4 (Antigen)) (Human-Mouse Monoclonal 5A8 Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal 5A8 Kappa-Chain, Dimer 
A humanized monoclonal antibody against CD4, with anti-human immunodeficiency virus (HIV) activity. Ibalizumab binds to CD4, the primary receptor for… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Monoclonal Antibodies

Narrower (2)

TMB-355TNX-355
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Monoclonal antibodies against infectious microbes: so long and too little!
Monoclonal antibodies (mAbs) as alternatives or more often as complementary to the conventional antimicrobials are being… 
2019
2019
Affinity Improvement of a Humanized Antiviral Antibody by Structure-Based Computational Design
Acquired immune deficiency syndrome (AIDS) is one of the most lethal infectious diseases influencing human community. While… 
Review
2019
Review
2019
Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
BACKGROUND Heavily treated HIV-1 infected patients may have limited therapeutic alternatives. In order to ensure sustained HIV… 
2018
2018
Rollout of high-priced cell and gene therapies forces payer rethink
2018
2018
Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.
Ibalizumab in Multidrug-Resistant HIV The FDA has recommended a streamlined trial design for assessing drugs’ safety and efficacy… 
2018
2018
Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
Over the past 30 years, antiretroviral drug regimens for treating HIV infection have become more effective, safer, and more… 
2018
2018
New Option for Drug-resistant HIV.
  • R. Voelker
  • Journal of the American Medical Association (JAMA…
  • 2018
  • Corpus ID: 5026859
2016
2016
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies
Background:Preexposure prophylaxis using antiretroviral agents has been shown to effectively prevent human immunodeficiency virus… 
2015
2015
Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Review
2007
Review
2007
Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
Tanox Inc (under license from Biogen Idec, formerly Biogen Inc) is developing ibalizumab, an intravenous, humanized, monoclonal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)